RT Book, Section A1 Papadakis, Maxine A. A1 McPhee, Stephen J. A1 Rabow, Michael W. A1 McQuaid, Kenneth R. SR Print(0) ID 1193123630 T1 Lipid Disorders Year in Review T2 Current Medical Diagnosis & Treatment 2023 YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264687343 LK accessmedicine.mhmedical.com/content.aspx?aid=1193123630 RD 2024/03/29 AB The FDA approved the novel PCSK9 inhibitor inclisiran, which uses silencing RNA technology to reduce liver production of PCSK9 protein by approximately 80%. Twice-yearly dosing is novel for lipid-lowering therapy; inclisiran enables new delivery strategies, including in-clinic administration.